Key result
From 1998 through 2022, the age-standardized mortality rate from cardiometabolic diseases in Mexico increased by 14.9%, and years of life lost increased by 0.4 years to reach 3.9 years in 2022.
Why the study?
Cardiometabolic diseases are highly prevalent in Mexico, prompting an analysis of national and state-level trends in CMD mortality and years of life lost from 1998 through 2022.
Observational
Yes
Mortality and years of life lost from cardiometabolic diseases have steadily increased in Mexico from 1998 to 2022, highlighting the need for robust prevention policies.
Answers are grounded in this paper and cite their sources.
Rising CMD mortality and YLL in Mexico signal urgent prevention needs; leaves open causal drivers and intervention effects.
OBJECTIVES: Cardiometabolic diseases (CMDs) are highly prevalent in Mexico. We analyzed the evolution of mortality from CMDs in Mexico at the national and state level, as well as their contribution to years of life lost (YLL), from 1998 through 2022. METHODS: We conducted an observational study based on a public database. We calculated age-standardized mortality rates, conducted joinpoint regression analyses to determine changes in the trend and magnitude of mortality over time, and calculated YLL from CMDs among people in Mexico nationally and by state. RESULTS: From 1998 through 2022, the age-standardized mortality rate from CMDs increased by 14.9% in Mexico. These rates reached their highest levels in 2020 and 2021 during the COVID-19 pandemic. In 2022, people aged 0 through 84 years had 3.9 YLL from CMDs, which represented an increase of 0.4 years compared with 1998. From 1998 through 2022, age-standardized mortality rates increased for heart disease, diabetes mellitus, and hypertension but decreased for stroke. CONCLUSIONS: Mortality and YLL from CMDs have steadily increased among people in Mexico, driven mainly by heart disease and diabetes mellitus. YLL attributable to CMDs could be prevented by early care and health prevention policies. Decision makers should work to implement robust and enduring health policies focused on shared risk factors underlying these diseases.
No takes yet. Share an insight, caveat, or question.
Agudelo‐Botero et al. (2025) conducted an observational in Cardiometabolic diseases. Time period (1998-2022) vs. 1998 was evaluated on Age-standardized mortality rate and years of life lost (YLL) from cardiometabolic diseases (14.9% increase). From 1998 through 2022, the age-standardized mortality rate from cardiometabolic diseases in Mexico increased by 14.9%, and years of life lost increased by 0.4 years to reach 3.9 years in 2022.
Synapse has enriched 10 related papers. Consider them for comparative context: